tert-butyl 4-(3-bromo-5-(trifluoromethyl)phenyl)piperazine-1-carboxylate

Catalog No. :
ACOFPN278
CAS No. :
444727-13-3
Molecular Formula :
C16H20BrF3N2O2
Molecular Weight :
409.25

IUPAC Name:tert-butyl 4-(3-bromo-5-(trifluoromethyl)phenyl)piperazine-1-carboxylate

tert-butyl 4-(3-bromo-5-(trifluoromethyl)phenyl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl 4-(3-bromo-5-(trifluoromethyl)phenyl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(3-bromo-5-(trifluoromethyl)phenyl)piperazine-1-carboxylate
MDL No.MFCD28400520
Molecular FormulaC16H20BrF3N2O2
Molecular Weight409.25
SMILESCC(C)(C)OC(=O)N1CCN(C2=CC(Br)=CC(C(F)(F)F)=C2)CC1
InChI KeyOIHZAJCEJWBQLB-UHFFFAOYSA-N
Synonymtert-butyl 4-(3-broMo-5-(trifluoroMethyl)phenyl)piperazine-1-carboxylate;tert-Butyl-4-[3-bromo-5-(trifluoromethyl)-phenyl]-1-piperazine Carboxylate;1-Piperazinecarboxylic acid, 4-[3-bromo-5-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester;1,1-Dimethylethyl 4-[3-bromo-5-(trifluoromethyl)phenyl]-1-piperazinecarboxylate;1-[3-Bromo-5-(trifluoromethyl)phenyl]-4-Boc-piperazine
CAS No.444727-13-3

Synthetic Route by SureRoute

1. ACOFPN278 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACEROH253 route compound structure diagram
    ACEROH253130723-13-6 In Stock
  4. Then
  5. ACOFPN278 route product structure diagram
    ACOFPN278444727-13-3
Inquiry

2. ACOFPN278 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOFPN278 route product structure diagram
    ACOFPN278444727-13-3
Inquiry

Comments (0)